ABSTRACT
The annual Eastern Canadian Gastrointestinal Cancer Consensus Conference 2017 was held in St. John's, Newfoundland and Labrador, 28-30 September. Experts in radiation oncology, medical oncology, surgical oncology, and cancer genetics who are involved in the management of patients with gastrointestinal malignancies participated in presentations and discussion sessions for the purpose of developing the recommendations presented here. This consensus statement addresses multiple topics in the management of gastric, rectal, and colon cancer, including â identification and management of hereditary gastric and colorectal cancer (crc);â palliative systemic therapy for metastatic gastric cancer;â optimum duration of preoperative radiation in rectal cancer-that is, short- compared with long-course radiation;â management options for peritoneal carcinomatosis in crc;â implications of tumour location for treatment and prognosis in crc; andâ new molecular markers in crc.
Subject(s)
Colorectal Neoplasms , Canada , Colorectal Neoplasms/pathology , Consensus , History, 21st Century , HumansABSTRACT
An example of the "two-eyed Scotty dog," seen on the oblique radiograph of the lumbar spine, is presented. The second eye is created by a prominent mammillary process.
Subject(s)
Lumbar Vertebrae/diagnostic imaging , Humans , Lumbar Vertebrae/anatomy & histology , Tomography, X-Ray ComputedABSTRACT
Bleomycin and mitomycin C have been reported to be active against advanced squamous cell carcinoma of the uterine cervix. Miyamoto et al reported a total response rate of 93% and complete response in 80% of the first 15 patients treated by sequential combination of bleomycin and mitomycin C. Updated results by Miyamoto reveal an 88.3% total response rate with a 65.3% complete response. However, others have reported poor results using the protocol outlined by Miyamoto. Using this protocol, 11 patients with advanced squamous cell carcinoma were treated at the authors' institution. There were no complete responses: one patient with partial response (9%), four with stable disease (36%), and six (55%) with progressive disease.
